The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients

Journal of Neural Transmission - 2020
Angelo Antonini1, Giovanni Abbruzzese2, Alfredo Berardelli3, Nicola Modugno4, I. Stroppa5, Filippo Tamma6, Mariachiara Sensi7, Francesca Mancini8, Giovanni Cossu9, Alessandro Stefani10, Nicola Tambasco11, Alessandro Tessitore12, Giovanni Fabbrini3, Francesco E. Pontieri13, Paolo Solla14, Anna Rita Bentivoglio15,16, Cristoforo Comi17, Brigida Minafra18, Giulio Riboldazzi19, Donato Melchionda20, Tommaso Martino20, Leonardo Lopiano21
1Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy
2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Child Health, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy
3Department of Human Neurosciences, Sapienza University of Rome, IRCCS Neuromed, Rome, Italy
4Parkinson Centre, IRCCS Neuromed, Pozzilli, Italy
5U.O. Dipartimentale di Endoscopia Digestiva Operativa e D’Urgenza, Policlinico Tor Vergata, Rome, Italy
6Neurology Unit, Miulli Hospital, Acquaviva delle Fonti, Italy
7Neurology Unit, Hospital Sant’Anna, Cona, Italy
8UO Neurologia e Stroke Unit e Laboratorio Neuroscienze, Istituto Auxologico San Luca, Milan, Italy
9SC Neurologia e Stroke Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy
10UOSD Parkinson, Fondazione Policlinico Tor Vergata, Rome, Italy
11Neurology Department, Perugia General Hospital University of Perugia, Perugia, Italy
12Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania, “Luigi Vanvitelli”, Caserta, Italy
13Department NESMOS, Sant’Andrea Hospital, “Sapienza” University, Rome, Italy
14Neurology Unit, Policlinico Universitario Monserrato, Cagliari, Italy
15Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
16Institute of Neurology, Università Cattolica del Sacro Cuore, Rome, Italy
17Neurology Unit, Parkinson’s Disease and Movement Disorders Centre, University of Piemonte Orientale, Novara, Italy
18Parkinson’s Disease and Movement Disorders Unit, IRCCS C. Mondino Foundation, Pavia, Italy
19Neurology Unit, Parkinson’s Disease and Movement Disorders Centre, ASST dei Sette Laghi, Varese, Italy
20S.C. Neurology, Neuroscience Department, A.O.U. Ospedali Riuniti, University of Foggia, Foggia, Italy
21Department of Neuroscience “Rita Levi-Montalcini”, University of Torino, Turin, Italy

Tóm tắt

Từ khóa


Tài liệu tham khảo

Antonini A, Nitu B (2018) Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm. https://doi.org/10.1007/s00702-018-1906-0

Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P (2010) Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 24:119–129

Antonini A, Odin P, Lopiano L, Tomantschger V, Pacchetti C, Pickut B, Gasser U, Calandrella D, Mancini F, Zibetti M, Minafra B, Bertaina I, Deyn P, Cras C, Wolf E, Spielberger S, Poewe W (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 120:1553–1558

Antonini A, Yegin A, Preda C, Bergmann L, Poewe W (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients: 12-month interim outcomes. Parkinsonism Relat Disord 21:231–235

Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, On behalf of the GLORIA study co-investigators (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20

Antonini A, Moro E, Godeiro C, Reichmann H (2018a) Medical and surgical management of advanced Parkinson's disease. Mov Disord 33:900–908

Antonini A, Robieson WZ, Bergmann L, Yegin A, Poewe W (2018b) Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. Neurodegener Dis Manag 8(3):161–170

Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin P (2018c) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin 20:1–11. https://doi.org/10.1080/03007995.2018.1502165

Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P (2011) Parkinson's disease: the non-motor issues. Parkins Rel Disord 17:717–723

Chaudhuri KR, Rizos A, Sethi KD (2013) Motor and non-motor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm 120:1305–1320

Contin M, Martinelli P (2010) Pharmacokinetics of levodopa. J Neurol 257:253–261

Cossu G, Ricchi V, Pilleri M, Mancini F, Murgia D, Ricchieri G, Mereu A, Melis M, Antonini A (2015) Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait. Neurol Sci 36(9):1683–1686. https://doi.org/10.1007/s10072-015-2234-x

Daley DJ, Myint PK, Gray RJ, Deane KH (2012) Systematic review on factors associated with medication non-adherence in Parkinson's disease. Parkinsonism Relat Disord 18(10):1053–1061

Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa induced dyskinesias. Mov Disord 22:1379–1389

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord 30:500–509

Grosset KA, Bone I, Grosset DG (2005) Suboptimal medication adherence in Parkinson's disease. Mov Disord 20(11):1502–1507

Kalia LV, Lang AE (2015) Parkinson disease. Lancet Neurol 386:896–912

Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Zangaglia R, Bentivoglio A, Eleopra R, Gualberti G, Melzi G, Antonini A (2019) Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 266(9):2164–2176

Lundqvist C, Beiske AG, Reiertsen O, Kristiansen IS (2014) Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. J Neurol 261:2438–2445

Malek N, Grosset DG (2015) Medication adherence in patients with Parkinson's disease. CNS Dugs 29:47–53

Nutt JG (2008) Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 23:S580–S584

Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM (2003) Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained- release tablets. Clin Neuropharmacol 26:156–163

Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, Othman A (2013) Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J 15:316–323

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149

Ondo WG (2014) Sleep/wake problems in Parkinson’s disease: pathophysiology and clinicopathologic correlations. J Neural Transm 121(Suppl 1):S3–13. https://doi.org/10.1007/s00702-014-1239-6

Palhagen SE, Sydow O, Johansson A, Nyholm D, Holmberg B, Widner H, Dizdar N, Linder J, Hauge T, Jansson R, Bergmann L, Kjellander S, Marshall TS (2016) Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord 29:17–23

Poewe W, Bergmann L, Kukreja P, Robieson WZ, Antonini A (2019) Levodopa-carbidopa intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety. J Parkinsons Dis 9(3):531–541

Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, Odin P, Antonini A, Chaudhuri KR (2012) Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol 35(5):205–207

Rispoli V, Andreasi Golfrè N, Penna G, Preda F, Contini E, Sensi M (2018) Levodopa/carbidopaintestinal gel infusion therapy: focus on gait and balance. Mov Disord Clin Pract. https://doi.org/10.1002/mdc3.12640

Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG, Sette E, Golfre-Andreasi N, Tugnoli V, Tola MR, Quatrale R (2014) Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm 121(6):633–642

Sensi M, Cossu G, Mancini F, Pilleri M, Zibetti M, Modugno N, Quatrale R, Tamma F, Antonini A (2017) Which patients discontinue? Issues on levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism Relat Disord 38:90–92. https://doi.org/10.1016/j.parkreldis.2017.02.020

Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J (2015) Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis 5:165–174

Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26:S1–S58

Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, Montanaro E, Reggio D, De Angelis C, Rizzone M, Lopiano L (2013a) Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. J Neurol 260:105–114

Zibetti M, Rizzone M, Merola A, Angrisano S, Rizzi L, Montanaro E, Cicolin A, Lopiano L (2013b) Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand 127(5):e28–32. https://doi.org/10.1111/ane.12075

Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L (2014) Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol 21:312–318

Zibetti M, Romagnolo A, Merola A, Priano L, Montanaro E, Angrisano S, Tribolo A, Cicolin A, Lopiano L (2017) A polysomnographic study in Parkinsonian patients treated with intestinal levodopa infusion. J Neurol 264(6):1085–1090. https://doi.org/10.1007/s00415-017-8491-2

Zibetti M, Angrisano S, Dematteis F, Artusi CA, Romagnolo A, Merola A, Lopiano L (2018) Effects of intestinal levodopa infusion on freezing of gait in Parkinson disease. J Neurol Sci 385:105–108

Thông tin
Thông tin xuất bản

Journal of Neural Transmission

Thông tin tác giả